Paul S. Ritch

Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different Schedules

George D. Demetri, Sant P. Chawla, Margaret von Mehren et al. · Journal of Clinical Oncology · 2009 · 536 citations · Full text

Medicine, Oncology, Pharmacology +15

HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma

Sunil R. Hingorani, Lei Zheng, Andrea J. Bullock et al. · Journal of Clinical Oncology · 2017 · 487 citations

Medicine, Oncology, Pharmacology +17

Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer

Susan Tsai, Ben George, D. Wittmann et al. · Annals of Surgery · 2018 · 227 citations

Medicine, Oncology, Pathology +13

Neoadjuvant FOLFIRINOX for Borderline Resectable Pancreas Cancer: A New Treatment Paradigm?

Kathleen K. Christians, Susan Tsai, Anna Mahmoud et al. · The Oncologist · 2014 · 190 citations · Full text

Medicine, Oncology, Surgery +17

Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium

Manish A. Shah, Yelena Y. Janjigian, Ronald G. Stoller et al. · Journal of Clinical Oncology · 2015 · 177 citations

Medicine, Oncology, Pharmacotherapy +17